To understand how a diabetes drug touches the vascular system, it helps to start with the hormone it mimics. GLP-1 is an incretin hormone released by enteroendocrine L-cells in the distal ileum and colon after a meal. When glucose or other nutrients arrive in the gut, these cells close ATP-dependent potassium channels, depolarize the membrane, open L-type calcium channels and secrete GLP-1 into the bloodstream. The hormone then amplifies insulin secretion from pancreatic beta cells by two- to three-fold compared with intravenous glucose, a phenomenon known as the incretin effect. It also delays gastric emptying and suppresses glucagon release. In type 2 diabetes, this incretin effect is blunted, partly through impaired GLP-1 function and reduced receptor expression, which is precisely why pharmacological boosting of the pathway has proven so effective.

Native GLP-1, however, is a fleeting molecule. The enzyme dipeptidyl peptidase-4 cleaves it within minutes, leaving a circulating half-life of roughly ninety seconds, so a substantial fraction of the hormone is inactivated before it ever reaches its targets. Therapeutic agonists were engineered to escape this fate. Exenatide, derived from a peptide found in the saliva of the Gila monster, survives for about 2.4 hours and was approved in 2005 for twice-daily injection. Liraglutide carries a fatty-acid side chain that binds reversibly to serum albumin, extending its half-life to 13 to 15 hours after subcutaneous injection. Semaglutide, dulaglutide and albiglutide push persistence further still, with half-lives long enough to permit once-weekly dosing. Tirzepatide adds a second layer of sophistication by engaging the receptor for the other incretin hormone, GIP, as well as GLP-1.

All of these molecules converge on a single target: the GLP-1 receptor, a class B G protein-coupled receptor of 463 amino acids found in the pancreas, gastrointestinal tract, lungs, kidneys, central nervous system and, in mice, monkeys and humans, the heart. When activated, the receptor can couple to the Gs protein to raise cyclic AMP, to Gq/11 to elevate intracellular calcium, and to beta-arrestin to trigger ERK1/2 signaling. Crucially, different ligands bias the receptor toward different downstream cascades, a property known as biased agonism. The review highlights this as one plausible explanation for why structurally distinct agonists do not lower blood pressure to the same degree: they are not simply switching the receptor on, they are steering it toward different intracellular programs.

The vascular story begins in the endothelium. In human umbilical vein endothelial cells exposed to GLP-1, receptor activation recruits the phosphatidylinositol 3-kinase/Akt pathway, which phosphorylates and activates endothelial nitric oxide synthase, raising the bioavailability of nitric oxide, the principal relaxing factor of the vessel wall. A parallel protein kinase A-dependent route to nitric oxide production operates alongside it. Together these converging pathways relax vascular smooth muscle and reduce peripheral resistance. Downstream, activation of AMP-activated protein kinase and suppression of nuclear factor-kappa B signaling cut vascular oxidative stress, adhesion molecule expression and inflammatory cytokine release, linking the acute vasoactive effects of the receptor to the slower, anti-atherosclerotic remodeling of the vessel wall.

The heart and kidneys contribute their own mechanisms. In atrial cardiomyocytes, GLP-1 receptor activation couples to Epac2, triggering the secretion of atrial natriuretic peptide, which raises cyclic GMP and promotes both vasodilation and renal sodium excretion. Direct natriuresis has been documented in healthy, obese and type 2 diabetic individuals, offering a plausible route by which plasma volume, and with it blood pressure, is reduced. Evidence from mouse studies further suggests that exendin-4 can dampen angiotensin II signaling in the kidney, inhibiting the transforming growth factor beta1 and Smad3 pathway that drives fibrosis. Yet here the literature fractures: a clinical study of dulaglutide found no significant changes in plasma renin activity, serum aldosterone or related neurohormonal markers, leaving the role of the renin-angiotensin-aldosterone system unresolved and flagged by the review as a priority for further investigation.

The clinical data, drawn from cardiovascular outcome trials and pooled analyses, paint a picture of modest but persistent effect. Exenatide at 10 micrograms twice daily reduced systolic pressure by a least-squares mean of 2.8 mmHg across 2,171 patients, with the largest difference, 8.2 mmHg versus placebo, seen in people whose baseline systolic pressure exceeded 150 mmHg. Once-weekly exenatide lowered systolic pressure by 1.6 mmHg in the EXSCEL trial of nearly 14,752 patients. Dulaglutide at 1.5 milligrams produced a 2 to 3 mmHg reduction evident within four weeks and sustained through 26 weeks, accompanied by a fall in 24-hour pulse pressure. Semaglutide at 1.0 milligram weekly lowered systolic pressure by 2.6 mmHg in SUSTAIN-6, and oral semaglutide matched that figure at week 83 in PIONEER-6. Liraglutide managed 1.2 mmHg over 36 months in LEADER, while lixisenatide achieved only 0.8 mmHg in ELIXA. Diastolic pressure, by contrast, was largely untouched.

Two patterns emerge from those numbers. First, the effect is drug-specific: agents differ by more than threefold in the magnitude of systolic reduction they deliver, consistent with the biased agonism observed at the receptor. Second, the benefit is conditional. People with normal blood pressure at baseline showed no between-group differences in the trials, suggesting that GLP-1 receptor agonists act as regulators of an elevated system rather than as blanket antihypertensives. The review also draws a careful temporal distinction that has muddied the literature. Acutely, GLP-1 receptor stimulation of sinoatrial node pacemaker cells and brainstem autonomic neurons raises heart rate and can transiently nudge mean arterial pressure upward, particularly after dose escalation. Chronically, sustained therapy produces a net systolic reduction as weight loss, improved glycemic control and the vascular, renal and anti-inflammatory mechanisms accumulate and outweigh the initial pressor response. The two effects operate on different timescales and are not contradictory, but conflating them has fueled apparent inconsistencies across studies.

What the mechanisms cannot yet claim is firm human validation. Aside from the natriuresis and endothelial function data, most of the mechanistic evidence comes from animal models and in vitro systems, and blood pressure was rarely a pre-specified primary endpoint in the major cardiovascular outcome trials from which the clinical numbers are extracted. That makes it difficult to determine whether the observed 1 to 3 mmHg reductions translate into meaningful antihypertensive benefit independent of glycemic control or weight loss, and head-to-head comparisons between agents are lacking. The review calls for trials that place blood pressure at the center of the design, translational studies in human subjects to confirm the proposed nitric oxide, atrial natriuretic peptide and renin-angiotensin pathways, and stratified analyses to identify which patients, most plausibly those with elevated baseline pressure and coexisting type 2 diabetes, stand to gain the most.

Even within those limits, the synthesis carries a striking implication. A drug class developed to restore a gut hormone signal has turned out to engage nearly every major axis of cardiovascular regulation: endothelial nitric oxide signaling, natriuretic peptide release, renal sodium handling, vascular inflammation and atherosclerotic plaque biology. Liraglutide has been shown to suppress angiotensin II-induced inflammatory cascades in vessel walls, preventing the expression of ICAM-1, VCAM-1 and P-selectin on endothelial cells and restoring nitric oxide levels. Exenatide modulates matrix metalloproteinases in human coronary artery cells and shifts macrophages from a pro-inflammatory M1 state toward a reparative M2 phenotype, stabilizing atherosclerotic lesions. Semaglutide and liraglutide reduce plaque development in mice through AMPK activation and lowered proinflammatory cytokines. The blood pressure effect, small as it is, may be the visible surface of a much deeper vascular reprogramming, and understanding it fully could determine how these blockbuster drugs are positioned in the broader campaign against cardiovascular disease.

Subject of Research: Blood pressure regulation by glucagon-like peptide-1 receptor agonists and its cardiovascular mechanisms

Article Title: Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

Article References: Alharbi, N. H. J. (2026). Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications. Pharmacology Research & Perspectives, 14(5), Article e70329. https://doi.org/10.1002/prp2.70329

Image Credits: AI Generated

DOI: 10.1002/prp2.70329

Keywords: GLP-1 receptor agonists, blood pressure, hypertension, type 2 diabetes, nitric oxide, endothelial function, natriuresis, atrial natriuretic peptide, cardiovascular outcomes, semaglutide, liraglutide, incretin effect

The study’s technical innovation lies in separating two DNA modifications that standard tools cannot distinguish. The most common epigenetic mark, 5-methylcytosine, or 5mC, typically silences gene expression when it appears in promoter regions. Under the action of TET enzymes, 5mC can be oxidized into 5-hydroxymethylcytosine, or 5hmC, a demethylation intermediate that often has the opposite effect and may activate genes. Traditional bisulfite sequencing, the workhorse of DNA methylation research, converts unmethylated cytosines to uracil but leaves both 5mC and 5hmC untouched, so the resulting measurement is actually a composite of the two marks. To untangle them, the researchers ran two parallel assays on the same DNA samples: targeted bisulfite sequencing to capture the combined signal, and APOBEC-coupled epigenetic sequencing, which uses an enzyme to label hydroxymethylated cytosines with glucose so they survive deamination while methylated and unmodified cytosines are converted. Subtracting the hydroxymethylation level from the composite level yielded what the team calls true methylation.

The study population was drawn from two established Chinese cohorts. Cases came from the China Antihypertensive Trial in Ischemic Stroke, a multicenter randomized trial of blood pressure management after stroke, from which 615 patients with imaging-confirmed ischemic stroke were selected. Controls, totaling 610 individuals, were frequency-matched by age and sex from the Prevention of Metabolic Syndrome and Multi-Metabolic Disorders Study, a community-based prospective cohort. The participants averaged 62 years of age, with roughly equal numbers of men and women in each group. As expected, stroke patients carried a heavier burden of metabolic risk factors, including hypertension, diabetes, obesity, hyperglycemia, and dyslipidemia, and the two groups also differed in education level. These characteristics were carefully accounted for in the statistical models, which adjusted for age, sex, education, smoking, drinking, body mass index, blood lipids, hypertension, and diabetes.

The target region spanned nine CpG sites in the NPPA promoter, located between 540 and 276 base pairs upstream of the transcription start site on chromosome 1. Genomic DNA extracted from peripheral blood mononuclear cells was processed through both sequencing pipelines, with stringent quality control: samples showing bisulfite conversion rates below 98 percent or average sequencing coverage under 20-fold were excluded. The nine CpG sites were then analyzed individually and collectively. For the gene-level analysis, the researchers employed the weighted truncated product method, which combines P values across multiple sites while weighting each by its regression coefficient, a strategy designed to detect joint effects that individual site analyses might miss when each contributes only a small share of the overall signal.

The methylation results were striking. At eight of the nine CpG sites, true methylation levels were significantly lower in stroke patients than in controls, and this hypomethylation was negatively associated with the risk of having an ischemic stroke. These associations survived correction for multiple testing using the false discovery rate approach, with all q values below 0.05. When the nine sites were considered together, the gene-based association was significant, and the mean methylation level across the region showed a clear dose-response relationship: each unit increase in mean true methylation corresponded to an odds ratio of 0.94 for stroke, with a 95 percent confidence interval of 0.91 to 0.97. Subgroup analyses revealed that the association was more pronounced among older participants, women, non-smokers, non-drinkers, and those with lower educational attainment, findings the authors suggest could guide the clinical application of epigenetic markers.

Hydroxymethylation told a different and more nuanced story. Although median hydroxymethylation levels at the assayed sites tended to be higher in stroke patients, only one CpG site, designated CpG2 and located at chromosome 1 position 11,908,348, showed a statistically significant positive association with stroke after covariate adjustment and multiple testing correction, with an odds ratio of 1.39 and a 95 percent confidence interval of 1.15 to 1.68. The gene-based test for hydroxymethylation was also significant, indicating a joint effect across the region, but the mean hydroxymethylation level alone did not distinguish cases from controls. Notably, CpG2 was the only site where both methylation and hydroxymethylation were independently associated with stroke, making it a particularly intriguing candidate for future precision interventions if the relevant technologies mature.

Beyond stroke risk, the researchers asked whether these epigenetic marks could predict recovery. They followed 598 of the 615 stroke patients, after excluding 17 lost to follow-up, and assessed functional outcome at three months using the modified Rankin Scale, an ordinal measure ranging from no symptoms to death. In ordered logistic regression models that additionally adjusted for stroke subtype, time from onset to hospitalization, stroke severity on the National Institutes of Health Stroke Scale, and treatment assignment, true methylation levels at all eight significant CpG sites were associated with a lower risk of scoring higher on the scale, meaning better neurological recovery. A complementary binary analysis defining poor outcome as a modified Rankin Scale score of 3 or higher produced consistent results. Hydroxymethylation, by contrast, showed no significant association with functional outcome at any site, and the gene-based test for hydroxymethylation and outcome was not significant.

The findings fit into a broader scientific context. Circulating ANP levels have previously been linked to ischemic stroke and to 90-day mortality and functional outcomes after stroke onset, and genetic variants in NPPA have been associated with both ANP levels and stroke susceptibility in studies of Chinese and Korean populations. Because promoter methylation generally suppresses gene expression, the observed hypomethylation in stroke patients is consistent with reports that stroke patients carry higher serum ANP levels, though the authors caution that a direct causal link between NPPA promoter methylation and ANP expression has not yet been verified; in their own earlier work, methylation at these same sites did not significantly predict serum proANP levels. Animal studies add another layer: mice experiments have shown that 5hmC can protect the brain from ischemic injury, and knockdown of the TET enzymes that generate 5hmC worsened brain degeneration in models of focal ischemia.

The study’s implications reach toward prevention and treatment. Because epigenetic modifications are chemically reversible, unlike fixed genetic variants, the CpG sites identified here could serve not only as biomarkers for risk stratification and prognosis but also as potential therapeutic targets. This is particularly relevant given the troubled history of ANP-targeted drugs such as sacubitril/valsartan and recombinant carperitide, whose clinical use has been limited by hypotension, angioedema, and fatalities in hospital settings. A deeper understanding of how the NPPA gene is regulated at the epigenetic level might open alternative routes to modulating the ANP pathway more safely.

The authors are careful to note the limitations of their work. As an observational study, it cannot determine whether altered methylation and hydroxymethylation in the NPPA promoter are causes, consequences, or mere companions of ischemic stroke. Residual confounding cannot be fully excluded despite extensive adjustment, and the findings, derived from Chinese adults, may not generalize to other ethnic or age groups. The absence of circulating ANP measurements in the current dataset leaves the mechanistic bridge between promoter marks and hormone levels unconfirmed. Nevertheless, by simultaneously quantifying true methylation and hydroxymethylation at identical CpG sites in a large case-control sample with prospective follow-up, the study demonstrates that the two marks carry distinct information about stroke risk and recovery, and it makes a compelling case that separating them should become standard practice in epigenetic epidemiology of complex disease.

Subject of Research: Associations of NPPA promoter DNA methylation and hydroxymethylation with ischemic stroke risk and functional outcome

Article Title: Associations of NPPA promoter true methylation and hydroxymethylation with ischemic stroke and its functional outcome

Article References: Yao, J., Song, L., Jiang, J., Zhang, J., Chen, L., Fan, W., Lu, Y., Zhang, X., Jing, J., Jin, Y., Zhang, M., Hao, Y., & Peng, H. (2024). Associations of NPPA promoter true methylation and hydroxymethylation with ischemic stroke and its functional outcome. Epigenetics Communications, 4(1), Article 6. https://doi.org/10.1186/s43682-024-00029-5

Image Credits: AI Generated

DOI: 10.1186/s43682-024-00029-5

Keywords: ischemic stroke, NPPA, atrial natriuretic peptide, DNA methylation, DNA hydroxymethylation, epigenetics, bisulfite sequencing, APOBEC-coupled epigenetic sequencing, modified Rankin Scale, functional outcome, biomarkers, case-control study